Akt Kinase-Interacting Protein1, a Novel Therapeutic Target for Lung Cancer With EGFR-activating and Gatekeeper Mutations

Oncogene - United Kingdom
doi 10.1038/onc.2012.446
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

EGFR Kinase Domain Mutations – Functional Impact and Relevance for Lung Cancer Therapy

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

DDX49 Is a Novel Biomarker and Therapeutic Target for Lung Cancer Metastases

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2020English

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

Cancer Research
Cancer ResearchOncology
2019English

Cotargeting EGFR and Autophagy Signaling: A Novel Therapeutic Strategy for Non-Small-Cell Lung Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Dual Inhibition of EGFR With Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

Cancer Discovery
Oncology
2014English

Influence of EGFR-activating Mutations on Sensitivity to Tyrosine Kinase Inhibitors in a KRAS Mutant Non-Small Cell Lung Cancer Cell Line

PLoS ONE
Multidisciplinary
2020English

OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients With EGFR Activating and T790M Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy